568 related articles for article (PubMed ID: 19515548)
1. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.
Korn S; Thielen A; Seyfried S; Taube C; Kornmann O; Buhl R
Respir Med; 2009 Nov; 103(11):1725-31. PubMed ID: 19515548
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
3. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
4. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
5. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma.
Humbert M; Berger W; Rapatz G; Turk F
Allergy; 2008 May; 63(5):592-6. PubMed ID: 18355388
[TBL] [Abstract][Full Text] [Related]
6. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
Busse WW; Massanari M; Kianifard F; Geba GP
Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
[TBL] [Abstract][Full Text] [Related]
8. Italian real-life experience of omalizumab.
Cazzola M; Camiciottoli G; Bonavia M; Gulotta C; Ravazzi A; Alessandrini A; Caiaffa MF; Berra A; Schino P; Di Napoli PL; Maselli R; Pelaia G; Bucchioni E; Paggiaro PL; Macchia L
Respir Med; 2010 Oct; 104(10):1410-6. PubMed ID: 20483574
[TBL] [Abstract][Full Text] [Related]
9. Improvement in quality of life with omalizumab in patients with severe allergic asthma.
Chipps B; Buhl R; Beeh KM; Fox H; Thomas K; Reisner C
Curr Med Res Opin; 2006 Nov; 22(11):2201-8. PubMed ID: 17076981
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab in the treatment of severe asthma: efficacy and current problems.
Pelaia G; Renda T; Romeo P; Busceti MT; Maselli R
Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
[TBL] [Abstract][Full Text] [Related]
12. Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma.
Massanari M; Milgrom H; Pollard S; Maykut RJ; Kianifard F; Fowler-Taylor A; Geba GP; Zeldin RK
Clin Pediatr (Phila); 2009 Oct; 48(8):859-65. PubMed ID: 19564449
[TBL] [Abstract][Full Text] [Related]
13. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.
Rottem M
J Asthma; 2012 Feb; 49(1):78-82. PubMed ID: 22149205
[TBL] [Abstract][Full Text] [Related]
15. One year treatment with omalizumab is effective and well tolerated in Japanese Patients with moderate-to-severe persistent asthma.
Ohta K; Yamamoto M; Sato N; Ikeda K; Miyamoto T
Allergol Int; 2010 Jun; 59(2):167-74. PubMed ID: 20179417
[TBL] [Abstract][Full Text] [Related]
16. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.
Brusselle G; Michils A; Louis R; Dupont L; Van de Maele B; Delobbe A; Pilette C; Lee CS; Gurdain S; Vancayzeele S; Lecomte P; Hermans C; MacDonald K; Song M; Abraham I
Respir Med; 2009 Nov; 103(11):1633-42. PubMed ID: 19619998
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
[TBL] [Abstract][Full Text] [Related]
19. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]